NCT04407234View on ClinicalTrials.gov

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

January 7, 2021

Study Completion Date

January 7, 2021

Conditions

OverweightObesityDiabetes Mellitus, Type 2

Interventions

DRUG

Tirzepatide

Tirzepatide administered SC.

DRUG

Acetaminophen

Acetaminophen administered orally.

Trial Locations (1)

33014

Clinical Pharmacology of Miami, Hialeah

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT04407234 - A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide | Biotech Hunter | Biotech Hunter